Tao Y, Pan Z K, Wang S, Wang L, Zhao W L
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):388-392. doi: 10.3760/cma.j.issn.0253-2727.2022.05.007.
To improve the positivity rate and accuracy of MYD88 mutation detection in patients with Waldenström macroglobulinemia (WM) . MYD88 mutation status was retrospectively evaluated in 66 patients diagnosed with WM in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from June 2017 to June 2021. The positivity rate and accuracy of the different methods and specimens for MYD88 mutation detection were analyzed. MYD88 mutations were detected in 51 of 66 patients with WM, with an overall positivity rate of 77%. The positivity rate of the next-generation sequencing (NGS) or allele-specific polymerase chain reaction (AS-PCR) was significantly higher than that of the first-generation Sanger sequencing (84% 71% 46%, <0.05) . For the different specimens, the positivity rate for the lymph nodes or bone marrow was significantly higher than that of peripheral blood (79% 84% 52%, <0.05) . The positivity rate of the MYD88 mutation in the lymph nodes, bone marrow, and peripheral blood determined by NGS was 86%, 90%, and 67%, respectively. The positivity rate in the lymph nodes, bone marrow, and peripheral blood detected by AS-PCR was 78%, 81%, and 53%, respectively. Thirty-nine patients with WM underwent ≥ 2 MYD88 mutation detections. The final MYD88 mutational status for each patient was used as the standard to determine the accuracy of the different methods and in different specimens. The accuracy of MYD88 mutation detection in the lymph nodes (=18) and bone marrow (=13) by NGS was significantly higher than that in the peripheral blood (=4) (100% 100% 75%, <0.05) . There was no statistically significant difference in the accuracy of MYD88 mutation detection by AS-PCR in the lymph nodes (=15) , bone marrow (=11) , or peripheral blood (=16) (93% 91% 88%, >0.05) . In the detection of the MYD88 mutation in patients diagnosed with WM, NGS or AS-PCR is more sensitive than Sanger sequencing. Lymph nodes and bone marrow specimens are better than peripheral blood specimens.
为提高华氏巨球蛋白血症(WM)患者MYD88突变检测的阳性率和准确性。回顾性评估了2017年6月至2021年6月在上海交通大学医学院附属瑞金医院确诊为WM的66例患者的MYD88突变状态。分析了MYD88突变检测的不同方法和标本的阳性率及准确性。66例WM患者中,51例检测到MYD88突变,总体阳性率为77%。二代测序(NGS)或等位基因特异性聚合酶链反应(AS-PCR)的阳性率显著高于一代桑格测序(84%、71%、46%,P<0.05)。对于不同标本,淋巴结或骨髓的阳性率显著高于外周血(79%、84%、52%,P<0.05)。NGS检测淋巴结、骨髓和外周血中MYD88突变的阳性率分别为86%、90%和67%。AS-PCR检测淋巴结、骨髓和外周血中MYD88突变的阳性率分别为78%、81%和53%。39例WM患者接受了≥2次MYD88突变检测。以每位患者最终的MYD88突变状态为标准,确定不同方法和不同标本的准确性。NGS检测淋巴结(n=18)和骨髓(n=13)中MYD88突变的准确性显著高于外周血(n=4)(100%、100%、75%,P<0.05)。AS-PCR检测淋巴结(n=15)、骨髓(n=11)或外周血(n=16)中MYD88突变的准确性无统计学差异(93%、91%、88%,P>0.05)。在确诊为WM的患者中检测MYD88突变时,NGS或AS-PCR比桑格测序更敏感。淋巴结和骨髓标本优于外周血标本。